ERLOCIP 150MG contains Erlotinib which belongs to the group of medicines called Cytostatic agents. It is used to treat advanced non-small cell lung cancer in adult patients. It can also be used to treat advanced, unresectable metastatic pancreatic cancer in adult patients in combination with gemcitabine. It can be prescribed to you either as an initial therapy or as an alternative therapy if your disease remains largely unchanged after initial chemotherapy, provided your cancer cells have specific EGFR mutations.
Erlotinib works by inhibiting the activity of a protein called epidermal growth factor receptor (EGFR), which is known to be responsible for the growth and spread of cancer cells. Avoid smoking while taking this medicine, because smoking could decrease the amount of the medicine in your blood. Always take this medicine at least 1 hour before or 2 hours after meals. Avoid concomitant treatment of this medicine with statins because it may increase the risk of muscle pain, tenderness or cramps. Before taking this medicine, inform your doctor if you are pregnant or breastfeeding.
The most common side effect of taking this medicine are skin rash, nausea, vomiting, stomach pain, depression, headache, weight loss and hair loss. Contact your doctor immediately if any of the above symptom worsens. ERLOCIP 150MG is not recommended for use in patients with severe liver or kidney disease and in children or adolescents under 18 years of age. Consult your doctor before taking.